SALIRI-based(raltitrexed plus irinotecan)therapy as a second-line treatment for patients with metastatic colorectal cancer(SALLY):A prospective,multicenter,non-interventional,registry study  

作　　者：Shuqui Qin Jin Li Aiping Zhou Yanqiao Zhang Xianglin Yuan Liangjun Zhu Baoli Qin Shan Zeng Lin Shen Ying Yuan Weibo Wang Jun Liang Xianwen Zhang Feng Ye Ping Chen HuaizhangWang Zhenyan Yu Lu Yue Yong Fang Jianping Xiong Jianwei Yang Yiye Wan Xianli Yin Wenling Wang Nong Xu XiaohongWang Zemin Xiao Huafang Su YingWang Kangsheng Gu Shuiping Tu Zishu Wang Bo Liu Xiaohua Hu Weixian Liu Xiaofeng Li 

机构地区：[1]Department of Oncology,Nanjing Tianyinshan Hospital,Nanjing,Jiangsu,P.R.China [2]Department of Medical Oncology,Shanghai East Hospital,Shanghai,P.R.China [3]Department of Medical Oncology,Cancer Hospital Chinese Academy of Medical Sciences,Beijing,P.R.China [4]Department of Gastroenterology,Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,P.R.China [5]Department of Medical Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,P.R.China [6]Department of Medical Oncology,Jiangsu Cancer Hospital,Nanjing,Jiangsu,P.R.China [7]Department of Gastroenterology,Liaoning Cancer Hospital&Institute,Shenyang,Liaoning,P.R.China [8]Department of Oncology,Xiangya Hospital,Central South University,Changsha,Hunan,P.R.China [9]Department of Medical Oncology,Beijing Cancer Hospital,Beijing,P.R.China [10]Department of Medical Oncology,The Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,P.R.China [11]Department of Chemotherapy,Shandong Provincial Hospital,Jinan,Shandong,P.R.China [12]Department of Medical Oncology,Peking University International Hospital,Beijing,P.R.China [13]Department of Medical Oncology,Northern Jiangsu People’s Hospital,Yangzhou,Jiangsu,P.R.China [14]Department of Medical Oncology,The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,P.R.China [15]Department of Medical Oncology,General Hospital of NingxiaMedical University,Yinchuan,Ningxia,P.R.China [16]Department of Integrated Chinese andWestern Medicine,Henan Cancer Hospital,Zhengzhou,Henan,P.R.China [17]Department of Medical Oncology,Mudanjiang Tumor Hospital,Mudanjiang,Heilongjiang,P.R.China [18]Department of Oncology,Qingdao Municipal Hospital(Group),Qingdao,Shandong,P.R.China [19]Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,P.R.China [20]Department of Medical Oncology,The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,P.R.China [21]Department of Abdominal On

出　　处：《Cancer Communications》2024年第8期910-914,共5页癌症通讯（英文）

摘　　要：Primary chemotherapy options for colorectal cancer(CRC)involve four key drugs:fluorouracils(5-FU),oxaliplatin,irinotecan and raltitrexed.The first-line regimen consists of 5-FU and leucovorin combined with oxaliplatin(FOLFOX),while the second-line regimen involves 5-FU and leucovorin combined with irinotecan(FOLFIRI)for metastatic CRC(mCRC)in China[1].

关 键 词：drugs chemotherapy FOLFIRI 

分 类 号：R73-37[医药卫生—肿瘤]